Vela Diagnostics to Offer Manual ViroKey SARS-CoV-2 RT-PCR Test
By HospiMedica International staff writers Posted on 04 Apr 2020 |
Image: Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Photo courtesy of Applied Biosystems)
Vela Diagnostics (Singapore) plans to offer its manual ViroKey SARS-CoV-2 RT-PCR Test after its validation is completed and is currently working with the US Food and Drug Administration (FDA) for securing Emergency Use Authorization (EUA) for the test. Vela is a provider of an automated IVD Next–Generation Sequencing (NGS) workflow in the global diagnostics market. VELA’s real-time PCR and NGS applications are available on an integrated Sentosa platform; this provides a unique ability to leverage one system for two workflows, while carrying out tests for various targets in order to answer current clinical and research questions, as well as to drive laboratory operational efficiency.
Vela’s ViroKey SARS-CoV-2 RT-PCR Test is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs from individuals meeting CDC SARS-CoV-2 clinical criteria (e.g., clinical signs and symptoms associated with SARS-CoV-2 infection) in conjunction with CDC SARS-CoV-2 epidemiological criteria (e.g., history of residence in, or travel to a geographic region with active SARS-CoV-2 transmission at the time of travel, or other epidemiologic criteria for which SARS-CoV-2 testing may be indicated).
The automated workflow is intended to be used on the Sentosa SX101 with the Sentosa SX Virus Total Nucleic Acid Kit v2.0 in conjunction with the Sentosa SA201 instrument for high-throughput RT-PCR. The assay also fits into a manual workflow for laboratories with existing Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.
Related Links:
Vela Diagnostics
Vela’s ViroKey SARS-CoV-2 RT-PCR Test is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs from individuals meeting CDC SARS-CoV-2 clinical criteria (e.g., clinical signs and symptoms associated with SARS-CoV-2 infection) in conjunction with CDC SARS-CoV-2 epidemiological criteria (e.g., history of residence in, or travel to a geographic region with active SARS-CoV-2 transmission at the time of travel, or other epidemiologic criteria for which SARS-CoV-2 testing may be indicated).
The automated workflow is intended to be used on the Sentosa SX101 with the Sentosa SX Virus Total Nucleic Acid Kit v2.0 in conjunction with the Sentosa SA201 instrument for high-throughput RT-PCR. The assay also fits into a manual workflow for laboratories with existing Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.
Related Links:
Vela Diagnostics
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans